



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q67403

YAGITA, Akikuni

Appln. No.: 09/998,429

Group Art Unit: 1651

Confirmation No.: 6046

Examiner: F. C. Prats

Filed: December 03, 2001

For: INTERLEUKIN-12 INDUCER AND MEDICAL COMPOSITION

REQUEST FOR RECONSIDERATION

MAIL STOP NON-FEE AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In response to the Office Action dated May 29, 2003, please consider the remarks as submitted herewith on the accompanying pages.

REMARKS

Applicants respectfully request reconsideration of the rejection set forth in the Office Action dated May 29, 2003.

The claims under consideration are claims 18-20.

At the middle of page 2 of the Office Action, claim 18 is rejected under 35 U.S.C. § 102(b) as being anticipated by Ghoneum I or Ghoneum II.

The Examiner states that each of the Ghoneum references discloses administering AHCC at a dosage rate of three grams per day, which is the dosage used by Applicant in the present